Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Alnylam Pharmaceuticals Inc (ALNY) reported strong financial performance with combined net product revenues of over $1.6 billion, achieving a 33% growth compared to 2023.
- The company achieved a significant milestone with $95 million in non-GAAP operating income for the full year, marking its first year of profitability.
- The HELIOS-B Phase III study yielded highly positive results, leading to the submission of global regulatory filings for vutrisiran in ATTR cardiomyopathy.
- Alnylam Pharmaceuticals Inc (ALNY) has a robust pipeline with numerous multibillion-dollar opportunities, including the advancement of Nucresiran, which received orphan drug designation for ATTR amyloidosis.
- The company maintained its award-winning culture, which has been a critical enabler of its success, and is poised for sustainable growth and value creation in 2025 and beyond.
- The launch of AMVUTTRA for ATTR cardiomyopathy is expected to face delays in formulary uptake, with meaningful demand anticipated only in the second half of 2025.
- Gross margin on product sales is expected to decrease in 2025 due to the increased royalty burden on AMVUTTRA sales.
- The company faces competition in the market, particularly in the polyneuropathy segment, which could impact its market share and growth.
- There is uncertainty regarding payer policies and the establishment of value-based agreements for the expanded label of AMVUTTRA in cardiomyopathy.
- Alnylam Pharmaceuticals Inc (ALNY) anticipates increased R&D and SG&A expenses in 2025, driven by clinical investments and the launch of AMVUTTRA, which could impact profitability.
Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals fourth-quarter full-year 2024 earnings conference call. (Operator Instructions)
I would now like to turn the conference call over to the company. Please go ahead.
Good morning. I'm Christine Lindenboom, Chief Corporate Communications Officer at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer. For those of you who participate a conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.
During today's call, as outlined on Slide 2, Yvonne will offer introductory remarks and provide general context. Tolga will provide an update on our global commercial progress. Pushkal will review pipeline updates and clinical progress, and Jeff will review
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
